Trial Profile
Study of eltrombopag dosing for treatment of chronic immune thrombocytopenia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Jul 2018
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; Therapeutic Use
- 30 Jul 2018 New trial record
- 22 Jul 2018 Results published in the British Journal of Clinical Pharmacology